Probenecid

Quick links to important sections

Probenecid

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Probenecid

Quick Facts

Property Description
Active Ingredient Probenecid
Form Oral Tablet
Pharmacological Class Uricosuric Agent
Common Therapeutic Purpose Management of high uric acid levels
Origin Synthetic Compound

What Type of Medication is Probenecid?

Probenecid is a prescription-only medication classified pharmacologically as a uricosuric agent, a drug category recognized for enhancing the body's elimination of uric acid. It is categorized as a renal tubular transport blocking agent, reflecting its highly targeted mechanism of action within the kidney. This compound is a synthetic derivative of benzoic acid, and its active ingredient, Probenecid (INN), is available under brands such as Benemid and Probalan, and is primarily administered as a single-component oral tablet for systemic administration.

How Does Probenecid Affect the Body's Chemistry?

The core function of Probenecid involves modulating processes in the kidney to achieve a state of uricosuria, or increased uric acid passage into the urine. It works by inhibiting specific transport mechanisms within the kidney tubules that would normally reabsorb uric acid back into the bloodstream. By blocking this reabsorption pathway, a greater quantity of uric acid is channeled out of the body, which serves as the core principle for long-term therapeutic management. Furthermore, Probenecid possesses a secondary function as an organic acid transport inhibitor, allowing it to delay the kidney’s excretion of various other organic acid compounds.

Composition and Chemical Identity of Probenecid

The active substance in the medicine is Probenecid, which has the chemical structure of p-(dipropylsulfamoyl)benzoic acid. This composition confirms its synthetic origin and its differentiation from other non-transport-modulating drugs. While its primary role is chronic uric acid management in adults, its established oral tablet form confirms its designation as a foundation for sustained, systemic biochemical therapy.

Regulatory References

  1. FDA Drug Label for Probenecid

What side effects are possible with Probenecid?

Probenecid's safety profile, as outlined in official regulatory documents, addresses adverse reactions across several System-Organ Classes (SOC) and outlines specific safety constraints. The official labeling describes effects ranging from systemic discomfort to rare, serious reactions.

Documented Adverse Reactions

Adverse reactions listed in regulatory documents involve multiple body systems. Effects on the gastrointestinal system may include nausea, vomiting, and loss of appetite. Genitourinary and renal effects include urinary frequency and the potential for uric acid stones. Dermatological reactions such as dermatitis, itching (pruritus), and hives (urticaria) are also documented. Additionally, hematologic disturbances like anemia and leukopenia are included in the official safety classification.

Serious Safety Considerations

The most serious adverse reactions are generally reported as rare. These low-frequency, high-impact events officially include anaphylaxis, aplastic anemia, hepatic necrosis, nephrotic syndrome, and severe skin reactions such as Stevens-Johnson syndrome (SJS). Regulatory information emphasizes that the appearance of any severe hypersensitivity reaction requires the cessation of therapy.

Population and Contextual Safety Constraints

The official label states specific safety limitations. Probenecid is contraindicated in children under 2 years of age and in individuals with pre-existing conditions such as blood dyscrasias or uric acid kidney stones. Furthermore, a time-related safety pattern is noted: the precipitation of acute gouty arthritis (gout flare) is a safety concern that may occur following the initiation of therapy.

Overdose and Emergency Response

The official regulatory information concerning Probenecid overdosage focuses primarily on the potential for acute, severe effects involving the central nervous system (CNS). Massive overdosage is documented to cause CNS stimulation and may lead to convulsions. The most serious, life-threatening outcome explicitly stated in regulatory texts associated with these effects is death from respiratory failure.

Emergency regulatory guidance mandates that for advice on managing an overdosage, individuals must contact a Poisons Information Centre or equivalent emergency medical services immediately. Immediate medical attention is required to manage any signs of overdose.

Management procedures officially described include general symptomatic and supportive measures. Specific interventions may involve the use of activated charcoal, ideally administered within one hour of ingestion. Furthermore, if signs of CNS excitation are present, regulatory documentation describes the potential need for parenteral administration of a short-acting barbiturate. It is noted in regulatory information that no specific antidote is documented or known for Probenecid overdosage. There are no population-specific considerations regarding overdose severity or management documented for groups such as the elderly or those with impaired renal function in the official regulatory sections.

Therapeutic Uses of Probenecid

Quick Facts

  • Chronic Gout: Helps manage the elevated uric acid levels associated with chronic gout and gouty arthritis.
  • Antibiotic Adjuvant: Used to support the sustained presence of certain penicillin antibiotics in the bloodstream.

What Probenecid Treats: Main Uses and Benefits

Probenecid is a prescription medication utilized in two principal therapeutic domains. Its primary approved use is for the management of hyperuricemia, a condition characterized by high uric acid levels in the blood, which is associated with chronic gout and gouty arthritis. The medication works to reduce the miscible urate pool, which may support the prevention of gout flares and promote the stabilization of existing urate deposits.

Additionally, Probenecid is indicated as an adjunct to antibiotic therapy. Specifically, it is administered alongside certain penicillins—such as ampicillin, methicillin, or penicillin G—to support the elevation and prolongation of the antibiotics' presence in the plasma. This usage supports the therapeutic benefit of the antibiotic course. Probenecid is utilized in these specific therapeutic contexts for medical management.

Regulatory References

  1. FDA therapeutic overview

Eligibility and Restrictions for Use

Who can and cannot use Probenecid?

Probenecid is primarily indicated for two main purposes: treating chronic gout and prolonging the effects of certain antibiotics (such as penicillin or ampicillin).

It is essential that a healthcare provider determines if this medication is appropriate for a patient, considering their overall health and other medications.


General Indications

Condition Use of Probenecid
Chronic Gout Primary treatment to reduce uric acid levels.
Antibiotic Therapy Used with certain antibiotics to maintain higher drug levels in the blood.

Contraindications (Who Should Not Use Probenecid)

Probenecid is generally contraindicated in patients with a few key conditions, as its use could worsen the condition or cause serious adverse effects. Patients must inform their doctor if they have any of the following:

  • Known hypersensitivity or allergy to probenecid.
  • A history of blood dyscrasias (e.g., bone marrow suppression).
  • An acute gout attack. Probenecid should not be started until the acute attack has subsided.
  • Kidney stones or impaired kidney function, especially with high uric acid levels, as it can initially increase the risk of stone formation.
  • Children under the age of 2 years.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Probenecid primarily interacts with other substances by inhibiting their renal excretion, leading to increased and prolonged plasma concentrations of the co-administered drug. This action is mediated through the competitive inhibition of Organic Anion Transporters (OATs) in the kidney.


Clinically Significant Interaction Categories

Interaction Type Examples of Interacting Substances
Increased Plasma Concentration Penicillins, most Cephalosporins, Acyclovir, Zidovudine, Indomethacin, Methotrexate, Acetaminophen
Antagonism of Efficacy Salicylates (Aspirin), Pyrazinamide
Enhanced Pharmacodynamic Effect Oral Sulfonylureas (e.g., Chlorpropamide), Coumarin Anticoagulants

Interaction-Related Restrictions and Considerations

  • Contraindicated Combinations: The co-administration of salicylates (including low-dose aspirin) is not recommended or restricted because they antagonize Probenecid's uricosuric effect. Co-administration with Methotrexate is restricted due to the significant risk of increased Methotrexate toxicity.
  • Glucuronidation Inhibition: Probenecid also inhibits the glucuronidation of drugs like acetaminophen and Rifampin, contributing to higher drug levels.
  • Population Note: The use of Probenecid to prolong the effect of antibiotics is not recommended in the presence of known renal impairment. Use of Probenecid with Cidofovir is recommended to reduce the antiviral's nephrotoxicity risk.

Mechanism of Action

How Probenecid Works

Probenecid's mechanism of action is defined by its role as a renal tubular transport blocking agent, primarily focused on modulating the renal transport of weak organic acids through two distinct mechanisms in the kidney.


Competitive Blockade of Uric Acid Reabsorption

This mechanism involves the competitive inhibition of the Urate Transporter 1 (URAT1) in the proximal renal tubule. By blocking this transporter, Probenecid functionally prevents uric acid from being reclaimed from the kidney filtrate back into the bloodstream. This inhibition initiates a physiological cascade that results in a sustained increase in the urinary excretion of uric acid (uricosuria), leading to a reduction in the systemic concentration of serum uric acid.


Inhibition of Renal Organic Acid Secretion

The drug exerts a secondary, independent mechanism by competitively blocking the Organic Anion Transporters (OATs), specifically OAT1 and OAT3. These transporters actively move various organic acid compounds, including certain drugs, from the blood into the kidney tubule for elimination. The inhibition of this secretion pathway reduces the renal clearance of OAT substrate drugs, which results in their prolonged half-life and elevated systemic plasma concentrations.

Dosage and Administration Information

Probenecid is administered exclusively via the oral route as a 500 mg tablet. Its dosing regimen is determined by the specific use case and follows established clinical protocols.

Dosing Protocols

Use Case Initial Dose Maintenance & Maximum Dose Frequency
Chronic Gout 250 mg twice a day for one week 500 mg twice a day, adjustable by 500 mg every 4 weeks (maximum 2000 mg/day) Twice daily (BID)
Antibiotic Adjunct N/A 500 mg Four times daily (QID)

Administration Conditions

Probenecid therapy for chronic gout must not be initiated until after an acute gout flare has subsided. If a flare occurs during treatment, the current Probenecid dose should be continued without alteration. Because urate tends to crystallize in acidic urine, maintaining a liberal fluid intake is standard practice, along with measures to maintain alkaline urine (e.g., using sodium bicarbonate or potassium citrate).

Use in Specific Populations

The medication is contraindicated in children under two years of age. For children aged 2–14 years requiring the medication as an antibiotic adjunct, the dosage is calculated based on weight or body surface area, with the daily amount divided into four doses. Probenecid may not be effective for chronic gout when the kidney's glomerular filtration rate is 30 mL/minute or less.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials and Study Design

Research has examined the drug's profile in studies involving adults. Information on patient suitability and safety profile requires discussion with a healthcare provider.

The drug was studied in several randomized, controlled clinical trials (RCTs). These studies, which involved a range of adult participants, utilized a double-blind, placebo-controlled design. The primary goal of this design was to examine differences in measures between the drug and an inactive control substance (placebo).


Results from Phase III Trials

Acute Treatment Setting

Studies were designed to evaluate the drug's relationship with the severity of acute migraines and the time to onset of relief. Key measures included the rate of pain freedom at two hours post-dose and the absence of most bothersome symptoms (such as nausea, photophobia, or phonophobia) at the same time point.

Research has explored measures of patient quality of life. The study populations included individuals with a history of both episodic and chronic migraines. The results of these trials reported the proportions of participants who met the pre-defined endpoints.

Preventative Treatment Setting

Studies examined the drug in the context of preventing chronic migraines. Other research explored the drug's relationship with changes in headache frequency over a three-month period. These trials monitored the average monthly migraine days (MMDs) in participants in both the drug and placebo groups.

Clinical trials were designed to examine whether the combination of the drug and standard preventative therapies differed in measured endpoints compared to monotherapy alone. These specific studies compared the measured endpoints in groups receiving the combination therapy versus those receiving only one treatment.


Specific Population Considerations

  • Elderly Patients: Studies involving patients over 65 years of age were limited.
  • Patients with Comorbidities: A history of heart disease was one factor examined in study exclusion criteria. Information on potential risks and suitability requires discussion with a healthcare provider.

Key Studies & References

  1. Uricosurics Pathway, Pharmacodynamics: Probenecid mechanism of action (URAT1, OATs)

Frequently Asked Questions (FAQ)

Common questions about Probenecid (FAQ)

Q: Does Probenecid help with the pain of a gout attack?

Regulatory documents state that Probenecid is indicated for chronic gout, which means long-term management of uric acid levels. Official instructions indicate that therapy is typically initiated only after an acute gout flare has subsided, suggesting its purpose is not for immediate pain relief.


Q: Is Probenecid used for any kidney problems?

Official information describes Probenecid as a renal tubular blocking agent that acts in the kidneys to influence uric acid clearance. However, it is not listed as a primary treatment for underlying kidney disease. Its use is generally not recommended when the kidney's filtration rate is too low.


Q: How quickly does Probenecid start working to lower uric acid?

Probenecid works over time to decrease serum uric acid levels. Official administration protocols state that any necessary dosage adjustments may be made in increments every four weeks. This gradual process allows the treatment to achieve and maintain normal urate levels based on laboratory testing.


Q: Do I need to take Probenecid forever once I start it?

The drug is intended to be continued at the dosage necessary to maintain normal serum urate levels. If acute attacks have been absent for six months or more and uric acid levels remain normal, official documents state that the maintenance dosage may be reviewed for reduction.


Q: What happens if I forget to take Probenecid for a few days?

Information from authoritative patient guides states that if a single dose is missed, it should be taken as soon as it is remembered. However, specific instructions for missing multiple days are not generally detailed in official regulatory documentation.


Q: Are there common side effects that usually go away?

Adverse reactions are listed in official documents across several systems. For some individuals, common effects such as headache, mild nausea, vomiting, or loss of appetite may occur, but some side effects may lessen as the body adjusts to the medicine.


Q: Is nausea a common side effect reported with Probenecid?

Yes, regulatory information documents that nausea is an effect on the gastrointestinal system that can be reported during use. Other related effects include vomiting and loss of appetite.


Q: Do people often report getting a rash from Probenecid?

Dermatological reactions are documented in official safety information. These include pruritus (itching) and dermatitis (rash) as potential side effects.


Q: Does Probenecid interact with common over-the-counter pain relievers?

Official warnings state that the use of salicylates (a class that includes aspirin) is contraindicated because they can reduce the drug's intended uric acid-lowering effect. Acetaminophen is cited in regulatory documents as a mild analgesic that may be used instead of salicylates.


Q: Is Probenecid safe for older adults to take?

Regulatory documents do not contain specific warnings or unique dose adjustments for older adults beyond those related to underlying conditions, such as renal impairment. Official research summaries note that study data specifically involving patients over 65 years of age is limited.


Q: Can women who are pregnant or breastfeeding use Probenecid?

Official information describes that the drug crosses the placental barrier and appears in cord blood. Case reports have not documented adverse fetal outcomes, though adequate, well-controlled studies are not available. The drug is also known to be excreted into human milk at low levels.


Q: Does taking Probenecid mean I can stop following a low-purine diet?

Once serum uric acid levels are maintained within normal limits, official documents indicate that the usual restriction of purine-producing foods may be somewhat relaxed. Official documents refer to this possibility, but adjustments to diet are typically discussed with a healthcare provider.


Q: How does Probenecid affect my need to drink water?

Official documents recommend a liberal fluid intake to help prevent potential issues like the formation of uric acid stones, which can be associated with the drug's use in gout patients. This practice is recommended in official documents to help prevent those issues.


Q: Is there an increased risk of gout flares when first starting Probenecid?

Official warnings indicate that an exacerbation of gout may occur following the initiation of therapy. For this reason, treatment is typically started after any acute attack has subsided.


Q: Do studies suggest Probenecid is effective for chronic gout?

Probenecid is formally indicated in regulatory documents for the treatment of hyperuricemia (high uric acid) associated with gout and gouty arthritis. Its mechanism promotes the removal of uric acid from the body.


Q: Is Probenecid available as a generic medicine?

Yes, regulatory documents list Probenecid as the generic name for the active pharmaceutical substance.


Q: Why is Probenecid sometimes given with certain antibiotics?

Probenecid is indicated for use as an adjunct (an additional treatment) to certain antibiotic therapies, such as with penicillin. Its purpose is to prolong the antibiotic's plasma concentrations by slowing its removal from the body.


Q: Are there any specific dietary concerns when taking Probenecid?

Official administration guidelines emphasize the importance of maintaining a liberal fluid intake and measures to ensure alkaline urine (non-acidic). These steps are recommended to help prevent potential kidney-related issues.


Q: What if I have an existing stomach ulcer, can I still use Probenecid?

Regulatory documents indicate that the drug is to be used with caution in individuals with a history of peptic ulcer.


Q: Does Probenecid cause changes in blood test results?

Official documents note the potential for hematologic disturbances, which include conditions like anemia and leukopenia. Furthermore, the drug may cause a reducing substance to appear in the urine that could potentially interfere with certain types of urine sugar tests.


Q: What is the approved duration of use for Probenecid?

For the treatment of chronic gout, the drug is intended to be continued at the dosage necessary to maintain normal serum urate levels. There is no predetermined end-date, but the dosage may be decreased after six months of symptom control.


Q: Does Probenecid need to be taken with food?

Authoritative patient information suggests that the drug may be taken with food if stomach upset or irritation occurs.


Q: Is Probenecid used to treat high blood pressure?

Regulatory documents list the drug's indications strictly as the treatment of hyperuricemia associated with gout and gouty arthritis, and as an adjunct to certain antibiotic therapies. High blood pressure is not listed as an indication.


Q: How is Probenecid different from allopurinol for gout?

Probenecid is classified as a uricosuric agent, which is a drug that primarily works by increasing the amount of uric acid the body removes through the urine. This is distinct from other classes of gout medication that work by blocking the production of uric acid.


Q: What is the difference between Probenecid and a xanthine oxidase inhibitor?

Probenecid is a uricosuric agent that acts to increase the excretion of uric acid from the body. A xanthine oxidase inhibitor (XOI) is a different class of drugs that acts to decrease the production of uric acid in the body.


Q: Can Probenecid be used by people with a history of kidney stones?

Official documents specify that the drug is not recommended for individuals with known uric acid kidney stones. This is a specific constraint noted in the official safety information.


Q: Is Probenecid linked to any liver problems?

Hepatic necrosis (a serious form of liver injury) is documented in regulatory documents as a rare, serious adverse reaction that has been reported. This is noted in the official safety classification.


Q: Can Probenecid be taken at the same time as colchicine?

Official documents confirm that if an acute gout flare occurs during Probenecid therapy, the current Probenecid dosage may be continued. Colchicine, which is used to manage acute attacks, can be given concurrently as needed.


Q: What research is available about the long-term use of Probenecid?

Official documents specify a maintenance regimen for long-term therapy, including directions for continuing the drug at the dose needed to maintain normal serum urate levels. This suggests its use is intended to be sustained as long as necessary to control hyperuricemia.


Q: Does Probenecid affect how other medications are eliminated from the body?

Yes, Probenecid's mechanism of action involves inhibiting the renal excretion of various compounds and drugs. This can lead to a reduction in the body's rate of clearing those substances, resulting in elevated levels.


Q: Can Probenecid be taken by people who don't have gout?

The drug is approved for two distinct purposes. In addition to treating the high uric acid associated with gout, it is also indicated for use as an adjunct to certain antibiotic therapies.

How should Probenecid be stored and disposed of?

How to Store and Dispose of Probenecid

Official regulatory guidelines define strict conditions for the storage and disposal of Probenecid to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Keep from freezing and away from excess heat.
Container & Environment Keep the medication in the original container, tightly closed. Protect from excess moisture and direct light.
Child Safety Store the medication out of the reach and sight of children.

Disposal Instructions

Unused or expired Probenecid must be properly discarded. Official disposal methods include using a community drug take-back program. Unless the medication is on a specific flush list, it should generally not be flushed down the toilet or poured down a drain. If a take-back program is unavailable, mix the medication with an undesirable substance, seal it in a bag, and place it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Probenecid found in:

A-Z Index: